Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Duh, E.
Right arrow Articles by Aiello, L. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Duh, E.
Right arrow Articles by Aiello, L. P.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 48, Issue 10 1899-1906, Copyright © 1999 by American Diabetes Association

ARTICLES

Vascular endothelial growth factor and diabetes: the agonist versus antagonist paradox

E Duh and LP Aiello
Wilmer Ophthalmological Institute, Johns Hopkins Hospital, Baltimore, Maryland, USA.

Much of the morbidity and mortality associated with diabetes is primarily attributable to sequelae of microvascular and macrovascular disease. Over the past decade, dramatic progress has been achieved in elucidating the fundamental processes underlying the pathogenesis of these complications. Angiogenic factors in particular now appear to play a pivotal role in the development of microvascular complications as well as the response to macrovascular disease. Hyperglycemia, other growth factors, advanced glycation end products, oxidative stress, and ischemia can increase growth factor expression. In some microvascular tissues, the result is pathologic neovascularization and increased vascular permeability. These responses account for much of the visual loss associated with diabetic retinopathy and may, in addition, serve a significant role in nephropathy and neuropathy. In contrast, recent data suggest that vascular collateralization resulting from ischemia-induced growth factor release in tissues compromised by macrovascular disease may be important in reducing clinical symptoms and tissue damage. This angiogenic response, which may be beneficial in coronary artery and peripheral limb disease, appears to be reduced in patients with diabetes. Thus, two apparently diametrically opposed therapeutic paradigms are arising for the treatment of vascular complications in diabetes. Indeed, growth factor antagonists have been used successfully in diabetes-related animal models to block angiogenic and permeability complications in the retina and kidney. Conversely, growth factor agonists have been successfully used to stimulate collateral vessel formation and reduce ischemic symptoms from macrovascular disease in the coronary arteries and peripheral limbs. Both of these approaches are currently being evaluated in clinical trials for their respective indications. Thus, as these divergent therapeutic modalities begin to enter the clinical arena, this apparent paradox necessitates careful consideration of the potential risks, benefits, and interactions of the opposing regimens. Using vascular endothelial growth factor as a classic example of growth factor involvement, we discuss the current preclinical and clinical data supporting these approaches and the implications arising from the probable coexistence of these two therapeutic modalities.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
L. Q.M. Chow and S. G. Eckhardt
In Reply
J. Clin. Oncol., July 1, 2007; 25(19): 2859 - 2861.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
A. S. Morss and E. R. Edelman
Glucose Modulates Basement Membrane Fibroblast Growth Factor-2 via Alterations in Endothelial Cell Permeability
J. Biol. Chem., May 11, 2007; 282(19): 14635 - 14644.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S.-i. Yamagishi, K. Nakamura, T. Matsui, Y. Inagaki, K. Takenaka, Y. Jinnouchi, Y. Yoshida, T. Matsuura, I. Narama, Y. Motomiya, et al.
Pigment Epithelium-derived Factor Inhibits Advanced Glycation End Product-induced Retinal Vascular Hyperpermeability by Blocking Reactive Oxygen Species-mediated Vascular Endothelial Growth Factor Expression
J. Biol. Chem., July 21, 2006; 281(29): 20213 - 20220.
[Abstract] [Full Text] [PDF]

Home page
 J Mol EndocrinolHome page
Y. S. Kang, Y. G. Park, B. K. Kim, S. Y. Han, Y. H. Jee, K. H. Han, M. H. Lee, H. K. Song, D. R. Cha, S. W. Kang, et al.
Angiotensin II stimulates the synthesis of vascular endothelial growth factor through the p38 mitogen activated protein kinase pathway in cultured mouse podocytes.
J. Mol. Endocrinol., April 1, 2006; 36(2): 377 - 388.
[Abstract] [Full Text] [PDF]

Home page
 Circ. Res.Home page
M. Ii, H. Takenaka, J. Asai, K. Ibusuki, Y. Mizukami, K. Maruyama, Y.-s. Yoon, A. Wecker, C. Luedemann, E. Eaton, et al.
Endothelial Progenitor Thrombospondin-1 Mediates Diabetes-Induced Delay in Reendothelialization Following Arterial Injury
Circ. Res., March 17, 2006; 98(5): 697 - 704.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
G. P. Fadini, S. Sartore, I. Baesso, M. Lenzi, C. Agostini, A. Tiengo, and A. Avogaro
Endothelial progenitor cells and the diabetic paradox.
Diabetes Care, March 1, 2006; 29(3): 714 - 716.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
G. P. Fadini and A. Avogaro
Autologous transplantation of granulocyte colony-stimulating factor- mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes.
Diabetes Care, February 1, 2006; 29(2): 478 - 479.
[Full Text] [PDF]

Home page
 Diabetes CareHome page
B. Zhou, P. Huang, and Z. C. Han
Autologous Transplantation of Granulocyte Colony-Stimulating Factor-Mobilized Peripheral Blood Mononuclear Cells Improves Critical Limb Ischemia in Diabetes: Response to Fadini and Avogaro
Diabetes Care, February 1, 2006; 29(2): 479 - 480.
[Full Text] [PDF]

Home page
 DiabetesHome page
A. K.H. Cheung, M. K.L. Fung, A. C.Y. Lo, T. T.L. Lam, K. F. So, S. S.M. Chung, and S. K. Chung
Aldose Reductase Deficiency Prevents Diabetes-Induced Blood-Retinal Barrier Breakdown, Apoptosis, and Glial Reactivation in the Retina of db/db Mice
Diabetes, November 1, 2005; 54(11): 3119 - 3125.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
N. Yamada, Y. Horikawa, N. Oda, K. Iizuka, N. Shihara, S. Kishi, and J. Takeda
Genetic Variation in the Hypoxia-Inducible Factor-1{alpha} Gene Is Associated with Type 2 Diabetes in Japanese
J. Clin. Endocrinol. Metab., October 1, 2005; 90(10): 5841 - 5847.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
F. C. Sasso, D. Torella, O. Carbonara, G. M. Ellison, M. Torella, M. Scardone, C. Marra, R. Nasti, R. Marfella, D. Cozzolino, et al.
Increased Vascular Endothelial Growth Factor Expression But Impaired Vascular Endothelial Growth Factor Receptor Signaling in the Myocardium of Type 2 Diabetic Patients With Chronic Coronary Heart Disease
J. Am. Coll. Cardiol., September 6, 2005; 46(5): 827 - 834.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
C. Treins, S. Giorgetti-Peraldi, J. Murdaca, M.-N. Monthouel-Kartmann, and E. Van Obberghen
Regulation of Hypoxia-Inducible Factor (HIF)-1 Activity and Expression of HIF Hydroxylases in Response to Insulin-Like Growth Factor I
Mol. Endocrinol., May 1, 2005; 19(5): 1304 - 1317.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
A. B. El-Remessy, M. Bartoli, D. H. Platt, D. Fulton, and R. B. Caldwell
Oxidative stress inactivates VEGF survival signaling in retinal endothelial cells via PI 3-kinase tyrosine nitration
J. Cell Sci., January 1, 2005; 118(1): 243 - 252.
[Abstract] [Full Text] [PDF]

Home page
 Pharmacol. Rev.Home page
A. Hoeben, B. Landuyt, M. S. Highley, H. Wildiers, A. T. Van Oosterom, and E. A. De Bruijn
Vascular Endothelial Growth Factor and Angiogenesis
Pharmacol. Rev., December 1, 2004; 56(4): 549 - 580.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
V. Thallas-Bonke, C. Lindschau, B. Rizkalla, L. A. Bach, G. Boner, M. Meier, H. Haller, M. E. Cooper, and J. M. Forbes
Attenuation of Extracellular Matrix Accumulation in Diabetic Nephropathy by the Advanced Glycation End Product Cross-Link Breaker ALT-711 via a Protein Kinase C-{alpha}-Dependent Pathway
Diabetes, November 1, 2004; 53(11): 2921 - 2930.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
G. S. Werner, E. Jandt, A. Krack, G. Schwarz, O. Mutschke, F. Kuethe, M. Ferrari, and H. R. Figulla
Growth Factors in the Collateral Circulation of Chronic Total Coronary Occlusions: Relation to Duration of Occlusion and Collateral Function
Circulation, October 5, 2004; 110(14): 1940 - 1945.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
D. R. Cha, Y. S. Kang, S. Y. Han, Y. H. Jee, K. H. Han, J. Y. Han, Y. S. Kim, and N. H. Kim
Vascular endothelial growth factor is increased during early stage of diabetic nephropathy in type II diabetic rats
J. Endocrinol., October 1, 2004; 183(1): 183 - 194.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
R A Kowluru and S Odenbach
Role of interleukin-1{beta} in the pathogenesis of diabetic retinopathy
Br. J. Ophthalmol., October 1, 2004; 88(10): 1343 - 1347.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
R. Marfella, K. Esposito, F. Nappo, M. Siniscalchi, F. C. Sasso, M. Portoghese, M. Pia Di Marino, A. Baldi, S. Cuzzocrea, C. Di Filippo, et al.
Expression of Angiogenic Factors During Acute Coronary Syndromes in Human Type 2 Diabetes
Diabetes, September 1, 2004; 53(9): 2383 - 2391.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
E. Larger, M. Marre, P. Corvol, and J.-M. Gasc
Hyperglycemia-Induced Defects in Angiogenesis in the Chicken Chorioallantoic Membrane Model
Diabetes, March 1, 2004; 53(3): 752 - 761.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
D. Ray, M. Mishra, S. Ralph, I. Read, R. Davies, and P. Brenchley
Association of the VEGF Gene With Proliferative Diabetic Retinopathy But Not Proteinuria in Diabetes
Diabetes, March 1, 2004; 53(3): 861 - 864.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
R. N. Frank
Diabetic Retinopathy
N. Engl. J. Med., January 1, 2004; 350(1): 48 - 58.
[Full Text] [PDF]

Home page
 Genes Dev.Home page
I. Adini, I. Rabinovitz, J. F. Sun, G. C. Prendergast, and L. E. Benjamin
RhoB controls Akt trafficking and stage-specific survival of endothelial cells during vascular development
Genes & Dev., November 1, 2003; 17(21): 2721 - 2732.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
A. B. El-Remessy, M. A. Behzadian, G. Abou-Mohamed, T. Franklin, R. W. Caldwell, and R. B. Caldwell
Experimental Diabetes Causes Breakdown of the Blood-Retina Barrier by a Mechanism Involving Tyrosine Nitration and Increases in Expression of Vascular Endothelial Growth Factor and Urokinase Plasminogen Activator Receptor
Am. J. Pathol., June 1, 2003; 162(6): 1995 - 2004.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
K. Hirata, T.-S. Li, M. Nishida, H. Ito, M. Matsuzaki, S. Kasaoka, and K. Hamano
Autologous bone marrow cell implantation as therapeutic angiogenesis for ischemic hindlimb in diabetic rat model
Am J Physiol Heart Circ Physiol, January 1, 2003; 284(1): H66 - H70.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
O. M. Tepper, R. D. Galiano, J. M. Capla, C. Kalka, P. J. Gagne, G. R. Jacobowitz, J. P. Levine, and G. C. Gurtner
Human Endothelial Progenitor Cells From Type II Diabetics Exhibit Impaired Proliferation, Adhesion, and Incorporation Into Vascular Structures
Circulation, November 26, 2002; 106(22): 2781 - 2786.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
A. Flyvbjerg, F. Dagnaes-Hansen, A. S. De Vriese, B. F. Schrijvers, R. G. Tilton, and R. Rasch
Amelioration of Long-Term Renal Changes in Obese Type 2 Diabetic Mice by a Neutralizing Vascular Endothelial Growth Factor Antibody
Diabetes, October 1, 2002; 51(10): 3090 - 3094.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
C. Treins, S. Giorgetti-Peraldi, J. Murdaca, G. L. Semenza, and E. Van Obberghen
Insulin Stimulates Hypoxia-inducible Factor 1 through a Phosphatidylinositol 3-Kinase/Target of Rapamycin-dependent Signaling Pathway
J. Biol. Chem., July 26, 2002; 277(31): 27975 - 27981.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
T. Awata, K. Inoue, S. Kurihara, T. Ohkubo, M. Watanabe, K. Inukai, I. Inoue, and S. Katayama
A Common Polymorphism in the 5'-Untranslated Region of the VEGF Gene Is Associated With Diabetic Retinopathy in Type 2 Diabetes
Diabetes, May 1, 2002; 51(5): 1635 - 1639.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
S. B. Koevary, J. Nussey, and S. Lake
Accumulation of Topically Applied Porcine Insulin in the Retina and Optic Nerve in Normal and Diabetic Rats
Invest. Ophthalmol. Vis. Sci., March 1, 2002; 43(3): 797 - 804.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
E. J. Duh, H. S. Yang, I. Suzuma, M. Miyagi, E. Youngman, K. Mori, M. Katai, L. Yan, K. Suzuma, K. West, et al.
Pigment Epithelium-Derived Factor Suppresses Ischemia-Induced Retinal Neovascularization and VEGF-Induced Migration and Growth
Invest. Ophthalmol. Vis. Sci., March 1, 2002; 43(3): 821 - 829.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
A. N. Witmer, H. G. Blaauwgeers, H. A. Weich, K. Alitalo, G. F. J. M. Vrensen, and R. O. Schlingemann
Altered Expression Patterns of VEGF Receptors in Human Diabetic Retina and in Experimental VEGF-Induced Retinopathy in Monkey
Invest. Ophthalmol. Vis. Sci., March 1, 2002; 43(3): 849 - 857.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
G. J. Mick, X. Wang, and K. McCormick
White Adipocyte Vascular Endothelial Growth Factor: Regulation by Insulin
Endocrinology, March 1, 2002; 143(3): 948 - 953.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
D.-H. Kang, J. Kanellis, C. Hugo, L. Truong, S. Anderson, D. Kerjaschki, G. F. Schreiner, and R. J. Johnson
Role of the Microvascular Endothelium in Progressive Renal Disease
J. Am. Soc. Nephrol., March 1, 2002; 13(3): 806 - 816.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. Lahdenranta, R. Pasqualini, R. O. Schlingemann, M. Hagedorn, W. B. Stallcup, C. D. Bucana, R. L. Sidman, and W. Arap
An anti-angiogenic state in mice and humans with retinal photoreceptor cell degeneration
PNAS, August 28, 2001; 98(18): 10368 - 10373.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
A. S. D. VRIESE, R. G. TILTON, M. ELGER, C. C. STEPHAN, W. KRIZ, and N. H. LAMEIRE
Antibodies against Vascular Endothelial Growth Factor Improve Early Renal Dysfunction in Experimental Diabetes
J. Am. Soc. Nephrol., May 1, 2001; 12(5): 993 - 1000.
[Abstract] [Full Text]

Home page
 DiabetesHome page
M. Emoto, T. Anno, Y. Sato, K. Tanabe, S. Okuya, Y. Tanizawa, A. Matsutani, and Y. Oka
Troglitazone Treatment Increases Plasma Vascular Endothelial Growth Factor in Diabetic Patients and Its mRNA in 3T3-L1 Adipocytes
Diabetes, May 1, 2001; 50(5): 1166 - 1170.
[Abstract] [Full Text]

Home page
 Am. J. Pathol.Home page
L. E. Benjamin
Glucose, VEGF-A, and Diabetic Complications
Am. J. Pathol., April 1, 2001; 158(4): 1181 - 1184.
[Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
E. Pinter, J. Haigh, A. Nagy, and J. A. Madri
Hyperglycemia-Induced Vasculopathy in the Murine Conceptus Is Mediated via Reductions of VEGF-A Expression and VEGF Receptor Activation
Am. J. Pathol., April 1, 2001; 158(4): 1199 - 1206.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
X. Xin, S. Yang, G. Ingle, C. Zlot, L. Rangell, J. Kowalski, R. Schwall, N. Ferrara, and M. E. Gerritsen
Hepatocyte Growth Factor Enhances Vascular Endothelial Growth Factor-Induced Angiogenesis in Vitro and in Vivo
Am. J. Pathol., March 1, 2001; 158(3): 1111 - 1120.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
G B ARDEN
The absence of diabetic retinopathy in patients with retinitis pigmentosa: implications for pathophysiology and possible treatment
Br. J. Ophthalmol., March 1, 2001; 85(3): 366 - 370.
[Full Text]

Home page
 J. Biol. Chem.Home page
S. Corvera, C. DiBonaventura, and H. S. Shpetner
Cell Confluence-dependent Remodeling of Endothelial Membranes Mediated by Cholesterol
J. Biol. Chem., September 29, 2000; 275(40): 31414 - 31421.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1999 by the American Diabetes Association.